Understanding the Serum Free Light Chain Assays. Anne L Sherwood, PhD Director of Scientific Affairs The Binding Site, Inc.

Similar documents
Freelite SFLC in CKD why use a different reference range? Dr Colin Hutchison Nephrologist Hawke s Bay DHB

Serum free light chain (SFLC) assays. Dr Sarah Sasson SydPath Registrar

Serum Free Light Chains should be the target of response evaluation in light chain myeloma rather than urines: results from the IFM 2009 trial

EDEMA IN A PATIENT WITH RECURRENT RESPIRATORY INFECTIONS - Case Report

Serum Free Light Chain Assay

Diagnosis of Amyloidosis. Maria M. Picken MD, PhD Loyola University Medical Center Chicago

Laboratory Examination

Amyloidosis: What to do and how to diagnose: An Update 2017

Review of the recent publications from the French group of myeloma on urine vs serum FLC analysis in MM

Importancia del laboratorio en el seguimiento clínico de pacientes con mieloma múltiple

Tarek ElBaz, MD. Prof. Internal Medicine Chief, Division of Renal Medicine Al Azhar University President, ESNT

Multiple Myeloma 101: Understanding Your Labs

Glistening, Skin-Colored Nodule

Sheena Surindran Grand Rounds 2/15/11

Amyloidosis. Maria M. Picken MD, PhD

Amyloidosis Information. A General Overview for Patients

Multiple Myeloma Advances for clinical pathologists & histopathologists

Clinical history. 73 yo man with chest pain Systemic hypertension and WG Stress EKG N Stress echocardiogram: Cardiac catheterization: no CAD

M-Protien, what to do next? Ismail A Sharif MD, FRCPc Internal Medicine Day 22 nd April 2016

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL RESPONSE ASSESSMENT MYELOMA CHAPTER 11C REVISED: SEPTEMBER 2016

Case Report Diaphragmatic Amyloidosis Causing Respiratory Failure: A Case Report and Review of Literature

Hematology 101. Rachid Baz, M.D. 5/16/2014

Expanding Spectrum of Diseases Associated with Plasma Cell Dyscrasias

Interesting case seminar: Native kidneys Case Report:

Serum Levels of Free Light Chain before and after Chemotherapy in Primary Systemic AL Amyloidosis

Corporate Medical Policy

FIBRILLARY GLOMERULONEPHRITIS DIAGNOSTIC CRITERIA, PITFALLS, AND DIFFERENTIAL DIAGNOSIS

MYE FORMS REVEALED RESPONSE CODES OBJECTIVES. Stringent Complete Response (scr) Complete Response (CR) I have no conflicts of interest to disclose

Familial Mediterranean Fever. By:Ismaeel Qattam

Analysis of Free Serum Light Chains in Patients Suffering from Multiple Myeloma Complicated by Light-Chain Amyloidosis

CASE REPORT Light chain multiple myeloma: an evaluation of its biochemical investigations

A.M.W. van Marion. H.M. Lokhorst. N.W.C.J. van de Donk. J.G. van den Tweel. Histopathology 2002, 41 (suppl 2):77-92 (modified)

Multiple myeloma Biological & Clinical Aspects Isabelle Vande Broek, MD, PhD

Incidence of amyloidosis over 3 years: the AMYPRO study

Cardiac Involvement is Underdiagnosed in Patients with Biopsy-Proven Systemic AL Amyloidosis

Multiple myeloma evolves from a clinically silent premalignant

Heart Failure Syndromes related to Unusual Cardiomyopathies

Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

Amyloid Arthropathy of the Hip Joint Associated with Multiple Myeloma: A Case Report

The Utility Of Congo Red Stain And Cytokeratin Immunostain In The Detection Of Primary Cutaneous Amyloidosis

Clinical features and outcomes of systemic amyloidosis with gastrointestinal involvement: a single-center experience

Instructions for Plasma Cell Disorders (PCD) Post-HCT Data (Form 2116 Revision 3)

CASE 3 AN UNUSUAL CASE OF NEPHROTIC SYNDROME

The ABCs of Waldenström s Macroglobulinemia (WM)

Amyloidosis and Waldenström s Macroglobulinemia

Generalized Primary Amyloid Lymphadenopathy

Hevylite assays de - convoluted. Dr Karthik Ramasamy Oxford University Hospitals

: A Study Examining the Prevalence of Transthyretin Mutations in Subjects Suspected of Having Cardiac Amyloidosis

Comparison of amyloid deposition in human kidney biopsies as predictor of poor patient outcome

Malcolm P. McTaggart, PhD, 1 Jindriska Lindsay, FRCPath, 2 and Edward M. Kearney, FRCPath 1 ABSTRACT

IMAGING IN CARDIAC AMYLOIDOSIS ; TRENDS IN DIAGNOSIS AND GUIDING THERAPY

A Problem with Cardiac Amyloidosis. Defining Amyloidosis. Typical Amyloid Heart. Definition of a double-blind study:

Management of Multiple Myeloma

Hevylite : a New Serum Test for Assessing Patients with Multiple Myeloma

Criteria for Disease Assessment Joan Bladé

Amyloidosis. Philip Hawkins National Amyloidosis Centre UCL & Royal Free Hospital, London

Research Article Prognostic Significance of Serum Free Light Chains in Chronic Lymphocytic Leukemia

Amyloidosis for Practicing Hematologists

Monoclonal Gammopathies and the Kidney. Tibor Nádasdy, MD The Ohio State University, Columbus, OH

Breast amyloidosis: a case report

Amyloidosis. James J. Stark, MD, FACP Medical Director Cancer Program Maryview Medical Center. Professor of Medicine Eastern Virginia Medical

V. Smoldering multiple myeloma

TESTS AND INVESTIGATIONS FOR MULTIPLE MYELOMA A guide for patients and caregivers

30 Diagnostic Cytopathology, Vol 37, No 1 ' 2008 WILEY-LISS, INC.

Amyloidosis is a generic term for a group of diseases

Original Article Primary localized amyloidosis of the urinary tract frequently mimics neoplasia: a clinicopathologic analysis of 11 cases

Primary Amyloidosis. Kihyun Kim Div. of Hematology/Oncology, Dept. of Medicine, Sungkyunkwan Univ. School of Medidine Samsung Medical Center

Jo Abraham MD Division of Nephrology University of Utah

Multiple Myeloma: diagnosis and prognostic factors. N Meuleman May 2015

Anaemias and other Pesky Haematology Questions

Multiple Myeloma Early Detection, Diagnosis, and Staging

Smoldering Myeloma: Leave them alone!

Amiloidosi AL: clinica, esami diagnostici e prognosi

Case Report AL-Amyloidosis Presenting with Negative Congo Red Staining in the Setting of High Clinical Suspicion: A Case Report

Update in Nuclear Imaging of Amyloidosis and Sarcoidosis

Histopathology: Glomerulonephritis and other renal pathology

Dr Ian Roberts Oxford. Oxford Pathology Course 2010 for FRCPath Illustration-Cellular Pathology. Oxford Radcliffe NHS Trust

Case 3. ACCME/Disclosure. Laboratory results. Clinical history 4/13/2016

Bone Marrow Core Biopsy Specimens in AL (Primary) Amyloidosis A Morphologic and Immunohistochemical Study of 100 Cases

Early View Article: Online published version of an accepted article before publication in the final form.

Amyloidosis is caused by extracellular deposition of

Clinical Study Serum Immunoglobulin Free Light Chain Assessment in IgG4-Related Disease

Corporate Medical Policy

Update on Treatments for Systemic Amyloidosis

reversing familial amyloid polyneuropathy naturally the raw vegan plant based detoxification regeneration workbook for healing patients volume 2

Dr Ian Roberts Oxford. Oxford Pathology Course 2010 for FRCPath Illustration-Cellular Pathology. Oxford Radcliffe NHS Trust

Case Report A Case of Proliferative Glomerulonephritis with Monoclonal IgG Deposits That Showed Predominantly Membranous Features

Velcade (bortezomib)

Multiple intra-renal pathological injury patterns in resistant myeloma

CARDIAC AMYLOIDOSIS IMAGING ERIC MARTIN MD

Corporate Presentation

Suspecting Tumors, or Could it be cancer?

Forms Revision: Myeloma Changes

THE NATIONAL ORGANIZATION FOR RARE DISORDERS (NORD) THE PHYSICIAN S GUIDE TO AMYLOIDOSIS

Diabetes, Obesity and Heavy Proteinuria

Diagnostic approach to cardiac amyloidosis: A case report

Plasma cell myeloma (multiple myeloma)

Myeloma Support Group: Now and the Horizon. Brian McClune, DO

Protocol. Hematopoietic Stem-Cell Transplantation for Primary Amyloidosis

Systemic amyloidosis with cardiac involvement

Transcription:

Understanding the Serum Free Light Chain Assays Anne L Sherwood, PhD Director of Scientific Affairs The Binding Site, Inc.

AL Amyloidosis: abnormality of proteins from Plasma Cells in the Bone Marrow Red Blood Cells Soft blood-forming tissue that fills the cavities of bone White Blood Cells: (B lymphocytes/ Plasma cells) Platelets

Plasma Cells produce Antibodies and Free Light Chains Kappa Lambda

Antibodies Are Made Up Of Heavy Chains And Light Chains Immunoglobulin (Antibody) Light Chains Heavy Chains

There Are Two Types Of Light Chains Kappa And Lambda Kappa Free Light Chains Lambda Free Light Chains

Cancer. 1956;9:262-272. Korngold Kappa Lipari Lambda

Normal vs AL Amyloidosis Normal Lots of different types of whole antibodies AL Amyloidosis Too much of a Toxic, precipitating light chain produced

What is AL Amyloidosis? AL = Antibody Light chain (a disease of protein misfolding) Amyl oid = Starch-like (Greek)

Primary [AL] Amyloidosis is a plasma cell disorder Kappa Lambda Kappa Abnormal Lambda Lambda Normal Healthy Plasma cells Mutated (diseased) Plasma cells

These abnormal light chains have mutations which make them sticky Multiple Myeloma FDG PET: Severe Diffuse (D) and Focal (F) Disease A F They bind together to form an amyloid protein complex B Amyloid proteins D accumulate D in target organs such as the D D HEART and KIDNEYS D D

AL Amyloidosis In AL amyloidosis, proteins which deposit can damage critical organs (e.g., heart, kidneys) Important to use testing to monitor disease and guide therapy

Free Light Chain Review Free light chains are normally found in the blood. Free light chains circulate in the blood at abnormally high levels in many patients with AL amyloidosis. Levels of FLCs are associated with the number of malignant plasma cells in a patient with AL Amyloid. In AL Amyloid, abnormal free light chains stick together to form amyloid protein which can damage important organs like the kidneys and heart.

Types of Systemic Amyloidosis Primary (AL) Amyloidosis Kappa or Lambda Immunoglobulin light chain associated Secondary (AA) Amyloidosis Amyloidosis secondary to another disorder (such as RA, psoriatic arthritis, inflammatory bowel disease, TB, leprosy, osteomyelitis, bronchiectasis) Serum Amyloid A associated Hereditary Amyloidosis Associated with certain genotypes TTR mutant transthyretin associated More than 25 different amyloid proteins have been identified!

Relative Frequency All All Others Others 15% 15% AL AL Amyloidosis 85% Amyloidosis 85%

Amyloidosis Incidence AL Amyloidosis Incidence in the population 1/5 th of Multiple Myeloma (Annual Incidence AL 9 per million per year) Palumbo, A, Rajkumar SV. Leukemia 23:449 2009 Kyle, RA, Rajkumar SV. N. Engl. J of Med 351:1860 2004 Bradwell, Serum Free Light Chain Analysis, 5 th ed, 2008, p 125

Overlapping Diseases AL Amyloidosis BOTH! Myeloma

Amyloid The definitive diagnostic test for amyloidosis is a tissue biopsy showing apple green birefringence when stained with congo red dye and viewed under a microscope using polarized light Pink deposits when stained with hematoxylin and eosin The pink deposits appear apple green with congo red staining and polarized light Glomerular amyloidosis

Plasma Cells Produce Intact Antibodies AND Free Light Chains Intact Antibodies Tests SPE and IFE Free light chain test = Freelite Plasma Cell Free Light Chains

The FreeLite Test Measures both types of Free Light Chains Kappa Free Light Chains Lambda Free Light Chains

FREELITE : Polyclonal Sheep Abs Only Bind to Free Light Chains Kappa Hidden surface heavy chain Antibody target Antibody target light chain Lambda

Total Light Chain Assay

Normal Ranges for Serum Free Light Chains Units (mg/l) Kappa: 3.3 19.4 mg/l Units (mg/dl) Kappa: 0.33 1.94 mg/dl Lambda: 5.7 26.3 mg/l Lambda: 0.57 2.63 mg/dl / ratio: 0.26 1.65 / ratio: 0.26 1.65

Examples May July = 385 mg/l

THERAPY AL amyloidosis Therapy KILLS ABNORMAL PLASMA CELLS LESS ABNORMAL PLASMA CELLS = FEWER LIGHT CHAINS + LESS AMYLOID

Lab Reports

Laboratory Variability Absolute values in the serum free light chain assay can vary from lab to lab Different analytical instruments Different kits for different instruments Normal lab to lab variation

Laboratory Variability If you change the laboratory where your serum free light chains are measured: If possible, obtain some of the last sample and run it along with the new sample or Establish a new baseline for your serum free light chain levels. The change in your absolute sflc level should not effect the clinical interpretation.

Additional Resources www.wikilite.com (web version of our red book ) Google Binding Site Email us info@thebindingsite.com Call The Binding site 800-633-4484 - Experts are on hand to assist you Understanding Serum Free Light Chain Assays (IMF booklet)

Q & A